Search Results - protective

6 Results

Sort By:

Amino Acid Substitutions Mutants of Anthrax Protective Antigen, Lethal Factor, and Edema Factor

Anthrax toxin proteins available for licensing. Bacillus anthracis hosts containing plasmids expressing the following proteins are available. (Host strains are generally BH480, or sometimes BH460. Modest amounts of purified proteins (10-50 mg) could also be provided): PA. Protective antigen, wild type PA-3M (PA D683A, L685E, Y688K) PA-3M Cys PA-U7 PA...

Published: 7/25/2024 | Inventor(s): Stephen Leppla

Keywords(s): Acid, AMINO, Anthrax, ANTIGEN, Edema, factor, Lethal, Listed LPM Ano as of 4/15/2015, Mutants, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protective, RM, SUBSTITUTIONS, VJXXXX, WIXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Research Materials

Linear Epitopes of Anthrax Toxin Protective Antigen for Development of a Peptide Vaccine

Bacillus anthracis is a gram-positive, spore-forming bacteria that causes anthrax infection in humans. CDC inventors have identified epitope sequences of B. anthracis protective antigen (PA) that may be useful for development of peptide-based anthrax vaccines. This invention also relates to methods for determining whether post-vaccination protection...

Published: 7/25/2024 | Inventor(s): Conrad Quinn, Jan Pohl, Pavel Svoboda, Shannon Dalton, Jarad Schiffer, Stephen Soroka, Vera Semenova

Keywords(s): Anthrax, ANTIGEN, Bacillus, biosecurity, Bioterrism, Bio-terrorism, Bioterrorist, BioWarfare, CDC Docket Import, CDC Docket Import CDC Prosecuting, DC1XXX, DC4XXX, DCXXXX, Development, DXXXXX, Epitopes, LINEAR, OID-NCIRD-DBD, PA, Peptide, Protection, Protective, toxin, Vaccine

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease

Engineered Anthrax Toxin Variants that Target Cancer

This technology describes the use of novel mutated anthrax protective antigen (PA) protein variants to target tumor cells and tumor vasculature. NIH scientists have engineered two PA variants that selectively complement one another and combine to form active octamers that target tumor cells. This controlled oligomeric activation of the PA proteins...

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Damilola Phillips, Clinton Leysath

Keywords(s): Anthrax, ANTIGEN, CB1BXX, CB1XXX, CBXXXX, COMPLEMENTARY, CXXXXX, ENGINEERED, exclusively, FORM, Octamers, Protective, That, toxin, VARIANTS

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics, TherapeuticArea > Immunology

Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology

Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Shihui Liu, Thomas Bugge, Diane Peters, Jie Liu, Alexander Wein, Kuang-Hua Chen, Christopher Bachran, Damilola Phillips, Henning Hansen, Sarah Arnett, Clinton Leysath

Keywords(s): Against, AMOUNTS, Anthrax, AnthraxToxins, ANTIGEN, B, CA1BXX, CB1AXX, CB1BXX, CB1XXX, CB3CXX, CBXXXX, Cells, Cell-Surface, CMG2, COMPLEMENTARY, CONTAIN, Containing, CXXXXX, Cytolethal, Distending, EFFICACY, Efficient, ENGINEERED, exclusively, Exploiting, FELINE, FELINE Leukemia, FORM, Fusion, fusion proteins, Having, High, IC2-PA, Identifying, Improved, Leppla, Listed LPM McCue as of 4/15/2015, MARKER, Metallo..., MULTIMERIC, Mutated, Nature, Octamers, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protective, Protein, proteins, SOLID, SPECIFICALLY, Specificity, Strong, TARGET, Targeting, That, THERAPY, toxin, TOXINS, tumor, Types, UAXXXX, VARIANTS, VASCULATURE, VETERINARY

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases

Recombinant Modified Bacillus anthracis Protective Antigen for Use in Vaccines

This invention relates to improved methods of preparing Bacillus anthracis protective antigen (PA) for use in vaccines. PA is a secreted, non-toxic protein with a molecular weight of 83 KDa. PA is a major component of the currently licensed human vaccine (Anthrax Vaccine Adsorbed, AVA). Although the licensed human vaccine has been shown to be effective...

Published: 7/25/2024 | Inventor(s): John Robbins, Stephen Leppla, Rachel Schneerson, M Rosovitz

Keywords(s): Anthrax, ANTIGEN, Chromosome 18 ring, Chymotrypsin-Sensitive, CREATION, Cutaneous anthrax, DAXXXX, DBXXXX, DC4XXX, DC6XXX, DCXXXX, DDXXXX, DELETIONS, DXXXXX, Furin-Cleavage..., Loop, MOLECULE, Protective, R 18, recombinant, rPA, STABLE, UAXXXX

Category(s): Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases, Application > Research Materials, TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Vaccines

Monoclonal Antibodies that Neutralize B. anthracis Protective Antigen (PA), Lethal Factor (LF) and Edema Factor (EF)

Anthrax, whether resulting from natural or bioterrorist-associated exposure, is a constant threat to human health. The lethality of anthrax is primarily the result of the effects of anthrax toxin, which has 3 components: a receptor-binding protein known as "protective antigen" (PA) and 2 catalytic proteins known as "lethal factor" (LF) and "edema factor"...

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Suzanne Emerson, Robert Purcell, Mahtab Moayeri, Zhaochun Chen

Keywords(s): Anthrax, antibodies, ANTIBODY, ANTIGEN, Chimpaneze, DA3XXX, DAXXXX, DB3XXX, DBXXXX, DC4XXX, DCXXXX, DDXXXX, DXXXXX, Edema, FACTORS, Lethal, monoclonal, Neutralize, Neutralizes, PA, Protective, That, toxin, UAXXXX

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Rare / Neglected Diseases, Application > Therapeutics, TherapeuticArea > Infectious Disease